A case of lipoatrophy with Lispro insulin without insulin pump therapy. 2004

Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008060 Lipodystrophy A collection of heterogenous conditions resulting from defective LIPID METABOLISM and characterized by ADIPOSE TISSUE atrophy. Often there is redistribution of body fat resulting in peripheral fat wasting and central adiposity. They include generalized, localized, congenital, and acquired lipodystrophy. Lipodystrophies
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D061267 Insulin Aspart Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain. Insulin-Aspart,B28-Asp-Insulin,Insulin B28asp,Insulin, Aspartic Acid(B28)-,NovoLog,NovoRapid,Aspart, Insulin,B28 Asp Insulin,B28asp, Insulin
D061268 Insulin Lispro Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES. 28(B)-Lys-29(B)-Pro-Insulin,28(B)-Lysine-29(B)-Prolineinsulin,Humalog,Humalog Kwikpen,Insulin, Lys(28B)-Pro(29B)-,Insulin, Lysyl(28B)-Prolyl(28B)-,LYSPRO,Lispro,Kwikpen, Humalog,Lispro, Insulin

Related Publications

Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán
January 2001, Diabetes care,
Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán
March 2003, Diabetes care,
Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán
December 2007, Pediatric diabetes,
Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán
January 1993, Experimental and clinical endocrinology,
Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán
May 2018, Journal of diabetes science and technology,
Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán
April 2008, Diabetes research and clinical practice,
Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán
November 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán
September 1999, Diabetes care,
Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán
September 2020, Folia medica,
Alfonso Arranz, and Victor Andia, and Antonio López-Guzmán
August 2003, Expert opinion on pharmacotherapy,
Copied contents to your clipboard!